Skip to content
Facebook Instagram Linkedin

LifeScienceHistory.com

History made daily

  • Home
  • DirectoryExpand
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • News and History
  • Cartoons
  • Small World
  • Earth is a RockExpand
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
LifeScienceHistory.com
History made daily
Home / Therapeutics - Page 29

Therapeutics

FDA Approved Daxxify, a New Anti-Wrinkle Drug
Biotechnology | FDA | Therapeutics

FDA Approved Daxxify, a New Anti-Wrinkle Drug

On Sept. 7, 2022, the U.S. Food and Drug Administration (FDA) announced it had approved Revance Therapeutics’ DAXXIFY…

Read More FDA Approved Daxxify, a New Anti-Wrinkle DrugContinue

University of Victoria BioInnovation Hub to enhance collaboration in BC’s life sciences sector
Biotechnology | Diagnostics | Disease | Medical Device | Medicine | Non-Profit Research | Therapeutics

University of Victoria BioInnovation Hub to enhance collaboration in BC’s life sciences sector

On Aug. 31, 2022, a new front-door to the University of Victoria opened to advance health and life…

Read More University of Victoria BioInnovation Hub to enhance collaboration in BC’s life sciences sectorContinue

$838 Million neurosciences center broke ground in Connecticut
Biotechnology | COVID-19 | Diagnostics | Neurology | Therapeutics

$838 Million neurosciences center broke ground in Connecticut

On Aug. 31, 2022, the Yale New Haven Hospital broke ground on the $838 million, 505,000 square foot…

Read More $838 Million neurosciences center broke ground in ConnecticutContinue

Pfizer and BioNTech completed submission to EMA for Omicron BA.4/BA.5 adapted bivalent vaccine
Biotechnology | COVID-19 | Pharmaceutical | Therapeutics | Vaccine

Pfizer and BioNTech completed submission to EMA for Omicron BA.4/BA.5 adapted bivalent vaccine

On Aug. 26, 2022, Pfizer and BioNTech announced they had completed a submission to the European Medicines Agency…

Read More Pfizer and BioNTech completed submission to EMA for Omicron BA.4/BA.5 adapted bivalent vaccineContinue

Roche announced U.S. FDA approval of Xofluza to treat influenza in children aged five years and older
Biotechnology | Diagnostics | Infectious Disease | Influenza | Therapeutics

Roche announced U.S. FDA approval of Xofluza to treat influenza in children aged five years and older

On Aug. 11, 2022, Roche announced that the U.S. Food and Drug Administration (FDA) had approved a supplemental…

Read More Roche announced U.S. FDA approval of Xofluza to treat influenza in children aged five years and olderContinue

FDA approved first targeted therapy for HER2-low breast cancer
Biotechnology | Diagnostics | Disease | Oncology | Radiology | Therapeutics | Women's Health

FDA approved first targeted therapy for HER2-low breast cancer

On Aug. 5, 2022, the U.S. Food and Drug Administration (FDA) approved Daiichi Sankyo’s Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV…

Read More FDA approved first targeted therapy for HER2-low breast cancerContinue

HHS announced 66 million doses of Moderna’s variant-specific COVID-19 vaccine booster for potential use in Fall and Winter 2022
Biotechnology | COVID-19 | Therapeutics | Vaccine

HHS announced 66 million doses of Moderna’s variant-specific COVID-19 vaccine booster for potential use in Fall and Winter 2022

On Jul. 29, 2022, the U.S. Department of Health and Human Services (HHS), in collaboration with the U.S….

Read More HHS announced 66 million doses of Moderna’s variant-specific COVID-19 vaccine booster for potential use in Fall and Winter 2022Continue

AlphaFold revealed the structure of the protein universe
Medicine | Therapeutics

AlphaFold revealed the structure of the protein universe

On Jul. 28, 2022, AlphaFold, in partnership with EMBL’s European Bioinformatics Institute (EMBL-EBI), announced they we’re releasing predicted…

Read More AlphaFold revealed the structure of the protein universeContinue

Bacteria that causes rare disease Melioidosis discovered in U.S. environmental samples
Biotechnology | CDC | Disease | Environmental | Therapeutics

Bacteria that causes rare disease Melioidosis discovered in U.S. environmental samples

On Jul. 27, 2022, the Centers for Disease Control and Prevention (CDC) announced that it had identified for…

Read More Bacteria that causes rare disease Melioidosis discovered in U.S. environmental samplesContinue

Patient with HIV achieved remission following stem cell transplant
Biotechnology | HIV | Non-Profit Research | Therapeutics

Patient with HIV achieved remission following stem cell transplant

On Jul. 27, 2022, City of Hope announced that a 66-year-old man who was diagnosed with HIV in…

Read More Patient with HIV achieved remission following stem cell transplantContinue

COVID-19 Vacations Redux
Biotechnology | Cartoons - Original | COVID-19 | Diagnostics | Medicine | NIH | Non-Profit Research | Pharmaceutical | Therapeutics | U.S. Congress | Vaccine

COVID-19 Vacations Redux

COVID-19 Vacations Redux iIlustrates once again the pits and perils vacation travelers face as they begin their Summer…

Read More COVID-19 Vacations ReduxContinue

Australia TGA granted provisional approval for Moderna’s COVID-19 vaccine in children aged six months to five years
Biotechnology | COVID-19 | Therapeutics | Vaccine

Australia TGA granted provisional approval for Moderna’s COVID-19 vaccine in children aged six months to five years

On Jul. 18, 2022, Moderna announced that the Therapeutic Goods Administration (TGA) in Australia had granted provisional registration…

Read More Australia TGA granted provisional approval for Moderna’s COVID-19 vaccine in children aged six months to five yearsContinue

U.S. Government secured 3.2 million doses of Novavax COVID-19 vaccine
COVID-19 | NIH | Therapeutics | Vaccine

U.S. Government secured 3.2 million doses of Novavax COVID-19 vaccine

On Jul. 11, 2022, Novavax announced an agreement with the U.S. Department of Health and Human Services (HHS),…

Read More U.S. Government secured 3.2 million doses of Novavax COVID-19 vaccineContinue

Pfizer and BioNTech submitted a variation to EMA for vaccination of children ages 6 months to less than 5 Years with COMIRNATY
Biotechnology | COVID-19 | Life Science History | Pharmaceutical | Therapeutics | Vaccine

Pfizer and BioNTech submitted a variation to EMA for vaccination of children ages 6 months to less than 5 Years with COMIRNATY

On Jul. 8, 2022, Pfizer and BioNTech announced that the companies had submitted a variation to the European…

Read More Pfizer and BioNTech submitted a variation to EMA for vaccination of children ages 6 months to less than 5 Years with COMIRNATYContinue

Novavax Nuvaxovid COVID-19 vaccine conditionally authorized in EU for adolescents aged 12 through 17
Biotechnology | COVID-19 | Infectious Disease | Therapeutics | Vaccine

Novavax Nuvaxovid COVID-19 vaccine conditionally authorized in EU for adolescents aged 12 through 17

On Jul. 5, 2022, Novavax announced that the European Commission (EC) had approved the expanded conditional marketing authorization…

Read More Novavax Nuvaxovid COVID-19 vaccine conditionally authorized in EU for adolescents aged 12 through 17Continue

Pfizer announced submission of New Drug Application to the U.S. FDA for PAXLOVID
Biotechnology | COVID-19 | FDA | Infectious Disease | Therapeutics

Pfizer announced submission of New Drug Application to the U.S. FDA for PAXLOVID

On Jun. 30 2022, Pfizer announced the submission of a New Drug Application (NDA) to the U.S. Food…

Read More Pfizer announced submission of New Drug Application to the U.S. FDA for PAXLOVIDContinue

COVID-19 Wheel of Fortune
Biotechnology | Cartoons - Original | COVID-19 | Diagnostics | Disease | FDA | Life Science History | Medicine | Non-Profit Research | Pharmaceutical | Therapeutics | U.S. Congress | Vaccine

COVID-19 Wheel of Fortune

Play the COVID-19 Wheel of Fortune and see how lucky you are! You have two wheels to choose…

Read More COVID-19 Wheel of FortuneContinue

Innovation Pharmaceuticals reported Brilacidin inhibited Omicron, Delta, Gamma and Alpha SARS-CoV-2 variants
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Therapeutics | Vaccine

Innovation Pharmaceuticals reported Brilacidin inhibited Omicron, Delta, Gamma and Alpha SARS-CoV-2 variants

On Jun. 23, 2022, Innovation Pharmaceuticals reported that Brilacidin, the Company’s defensin-mimetic drug candidate exhibiting broad-spectrum antiviral activity,…

Read More Innovation Pharmaceuticals reported Brilacidin inhibited Omicron, Delta, Gamma and Alpha SARS-CoV-2 variantsContinue

Benaroya Research Institute received $11.4 million to explore link between viruses and immune system diseases
Biotechnology | Diagnostics | Non-Profit Research | Therapeutics

Benaroya Research Institute received $11.4 million to explore link between viruses and immune system diseases

On Jun. 17, 2022, Benaroya Research Institute at Virginia Mason (BRI) announced a 5-year, $11.4 million grant from…

Read More Benaroya Research Institute received $11.4 million to explore link between viruses and immune system diseasesContinue

Pfizer and BioNTech provided update on rolling submission to EMA for potential variant-adapted vaccine
COVID-19 | Pharmaceutical | Therapeutics | Vaccine

Pfizer and BioNTech provided update on rolling submission to EMA for potential variant-adapted vaccine

On Jun. 15, 2022, Pfizer and BioNTech announced the European Medicines Agency (EMA) had initiated a rolling review…

Read More Pfizer and BioNTech provided update on rolling submission to EMA for potential variant-adapted vaccineContinue

Oragenics announced publication of positive data for NT-CoV2-1 intranasal COVID-19 vaccine candidate in Scientific Reports
Biotechnology | Therapeutics | Vaccine

Oragenics announced publication of positive data for NT-CoV2-1 intranasal COVID-19 vaccine candidate in Scientific Reports

On Jun. 14 2022, Oragenics announced the publication of an article co-authored by Oragenics and collaborators at Inspirevax…

Read More Oragenics announced publication of positive data for NT-CoV2-1 intranasal COVID-19 vaccine candidate in Scientific ReportsContinue

Pfizer reported additional data on PAXLOVID supporting New Drug Application submission to U.S. FDA
Biotechnology | COVID-19 | Infectious Disease | Therapeutics

Pfizer reported additional data on PAXLOVID supporting New Drug Application submission to U.S. FDA

On Jun. 14 2022, Pfizer reported data from the Phase 2/3 EPIC-SR (Evaluation of Protease Inhibition for COVID-19…

Read More Pfizer reported additional data on PAXLOVID supporting New Drug Application submission to U.S. FDAContinue

Moderna announced Omicron-containing bivalent booster candidate mRNA-1273.214 demonstrated superior antibody response against Omicron
Biotechnology | COVID-19 | Infectious Disease | Therapeutics | Vaccine

Moderna announced Omicron-containing bivalent booster candidate mRNA-1273.214 demonstrated superior antibody response against Omicron

On Jun. 8, 2022, Moderna announced new clinical data on its Omicron-containing bivalent COVID booster candidate, mRNA-1273.214, containing…

Read More Moderna announced Omicron-containing bivalent booster candidate mRNA-1273.214 demonstrated superior antibody response against OmicronContinue

Zoetis Announces Agreement to Acquire Basepaws, an Innovative Leader in Petcare Genetics
Biotechnology | Diagnostics | Disease | Genomics | Therapeutics | Veterinary

Zoetis Announces Agreement to Acquire Basepaws, an Innovative Leader in Petcare Genetics

On Jun. 7, 2022, Zoetis announced an agreement to acquire Basepaws, a privately held petcare genetics company, which…

Read More Zoetis Announces Agreement to Acquire Basepaws, an Innovative Leader in Petcare GeneticsContinue

Merck and Ridgeback announcd data for investigational LAGEVRIO (molnupiravir) from Phase 3 MOVe-OUT study
Biotechnology | COVID-19 | Therapeutics

Merck and Ridgeback announcd data for investigational LAGEVRIO (molnupiravir) from Phase 3 MOVe-OUT study

On Jun. 7, 2022, Merck and Ridgeback Biotherapeutics announced the Annals of Internal Medicine had published additional data…

Read More Merck and Ridgeback announcd data for investigational LAGEVRIO (molnupiravir) from Phase 3 MOVe-OUT studyContinue

Veru submitted EUA to U.S. FDA for Sabizabulin, its anti-Inflammatory drug candidate for hospitalized COVID-19 patients
COVID-19 | FDA | Therapeutics

Veru submitted EUA to U.S. FDA for Sabizabulin, its anti-Inflammatory drug candidate for hospitalized COVID-19 patients

On Jun. 7, 2022, Veru announced that is had submitted an emergency use authorization (EUA) application to the…

Read More Veru submitted EUA to U.S. FDA for Sabizabulin, its anti-Inflammatory drug candidate for hospitalized COVID-19 patientsContinue

Pfizer announced investment $120 million to produce COVID-19 oral treatment in the U.S.
Biotechnology | COVID-19 | Infectious Disease | Therapeutics

Pfizer announced investment $120 million to produce COVID-19 oral treatment in the U.S.

On Jun. 6, 2022, Pfizer further strengthened its commitment to United States manufacturing with a $120 million investment…

Read More Pfizer announced investment $120 million to produce COVID-19 oral treatment in the U.S.Continue

Moderna and the European Commission agreed on amendment to COVID-19 vaccine supply agreement
Biotechnology | COVID-19 | Infectious Disease | Therapeutics | Vaccine

Moderna and the European Commission agreed on amendment to COVID-19 vaccine supply agreement

On Jun. 2, 2022, Moderna announced an agreement with the European Commission (EC) to amend their originally agreed…

Read More Moderna and the European Commission agreed on amendment to COVID-19 vaccine supply agreementContinue

NIH study confirmed benefit of supplements for slowing age-related macular degeneration
Biotechnology | Disease | Medicine | NIH | Ophthalmogy | Therapeutics

NIH study confirmed benefit of supplements for slowing age-related macular degeneration

On Jun. 2, 2022, the National Institutes of Health (NIH) reported that the Age-Related Eye Disease Studies (AREDS…

Read More NIH study confirmed benefit of supplements for slowing age-related macular degenerationContinue

Moderna and Takeda announced plans to transfer Marketing Authorization for Spikevax(TM) COVID-19 vaccine in Japan
Biotechnology | COVID-19 | Infectious Disease | Therapeutics | Vaccine

Moderna and Takeda announced plans to transfer Marketing Authorization for Spikevax(TM) COVID-19 vaccine in Japan

On May 31, 2022, Moderna and Takeda announced the transfer of the marketing authorization for Moderna’s COVID-19 vaccine…

Read More Moderna and Takeda announced plans to transfer Marketing Authorization for Spikevax(TM) COVID-19 vaccine in JapanContinue

Page navigation

Previous PagePrevious 1 … 27 28 29 30 31 … 117 Next PageNext
  • Categories
  • Timeline
  • Aesthetics
  • Agriculture
  • Artificial Intelligence
  • Biology
  • Biotechnology
  • Cardiology
  • Cartoons – Historical
  • Cartoons – Original
  • CDC
  • CDMO
  • Chemistry
  • Clinical Research
  • Cloning
  • CMO
  • COVID-19
  • CRISPR
  • CRO
  • Cryogenic
  • Dentistry
  • Diagnostics
  • Disease
  • Energy
  • Environmental
  • EPA
  • FDA
  • Forestry
  • Genomics
  • HIV
  • Infectious Disease
  • Influenza
  • IRB
  • Life Science History
  • Marine Science
  • Materials
  • Measles
  • Medical Device
  • Medicine
  • Nanotechnology
  • Neurology
  • NIH
  • Non-Profit Research
  • Nutraceuticals
  • Olfactory
  • Oncology
  • Ophthalmogy
  • Organ Transplant
  • Orthopedic
  • Other
  • Pharmaceutical
  • Plague
  • Polio
  • Prehistory
  • Quantum
  • Radiology
  • Rare Disease
  • Stem Cell
  • Therapeutics
  • U.S. Congress
  • Uncategorized
  • USDA
  • Vaccine
  • Veterinary
  • WHO
  • Women's Health
  • 2026
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005
  • 2004
  • 2003
  • 2002
  • 2001
  • 2000
  • 1999
  • 1998
  • 1997
  • 1996
  • 1995
  • 1994
  • 1993
  • 1992
  • 1991
  • 1990
  • 1989
  • 1988
  • 1987
  • 1986
  • 1985
  • 1984
  • 1983
  • 1982
  • 1981
  • 1980
  • 1979
  • 1978
  • 1977
  • 1976
  • 1975
  • 1974
  • 1973
  • 1972
  • 1971
  • 1970
  • 1969
  • 1968
  • 1967
  • 1966
  • 1965
  • 1964
  • 1963
  • 1962
  • 1961
  • 1960
  • 1959
  • 1958
  • 1957
  • 1956
  • 1955
  • 1954
  • 1953
  • 1952
  • 1951
  • 1950
  • 1949
  • 1948
  • 1947
  • 1946
  • 1945
  • 1944
  • 1943
  • 1942
  • 1941
  • 1940
  • 1939
  • 1938
  • 1937
  • 1936
  • 1935
  • 1934
  • 1933
  • 1932
  • 1931
  • 1930
  • 1929
  • 1928
  • 1927
  • 1926
  • 1925
  • 1924
  • 1923
  • 1922
  • 1921
  • 1920
  • 1919
  • 1918
  • 1917
  • 1916
  • 1915
  • 1914
  • 1913
  • 1912
  • 1911
  • 1910
  • 1909
  • 1908
  • 1907
  • 1906
  • 1905
  • 1904
  • 1903
  • 1902
  • 1901
  • 1900
  • 1899
  • 1898
  • 1897
  • 1896
  • 1895
  • 1894
  • 1893
  • 1892
  • 1891
  • 1890
  • 1889
  • 1888
  • 1887
  • 1886
  • 1885
  • 1884
  • 1883
  • 1882
  • 1881
  • 1880
  • 1879
  • 1878
  • 1877
  • 1876
  • 1875
  • 1874
  • 1873
  • 1872
  • 1871
  • 1870
  • 1869
  • 1868
  • 1867
  • 1866
  • 1865
  • 1864
  • 1863
  • 1862
  • 1861
  • 1860
  • 1859
  • 1858
  • 1857
  • 1856
  • 1855
  • 1854
  • 1853
  • 1852
  • 1851
  • 1850
  • 1849
  • 1848
  • 1847
  • 1846
  • 1845
  • 1844
  • 1843
  • 1842
  • 1840
  • 1839
  • 1838
  • 1837
  • 1836
  • 1834
  • 1833
  • 1832
  • 1831
  • 1830
  • 1828
  • 1827
  • 1826
  • 1825
  • 1824
  • 1823
  • 1820
  • 1819
  • 1818
  • 1817
  • 1816
  • 1813
  • 1811
  • 1810
  • 1809
  • 1808
  • 1804
  • 1802
  • 1801
  • 1800
  • 1799
  • 1798
  • 1796
  • 1795
  • 1794
  • 1793
  • 1790
  • 1789
  • 1788
  • 1786
  • 1785
  • 1784
  • 1782
  • 1781
  • 1777
  • 1769
  • 1765
  • 1761
  • 1753
  • 1751
  • 1749
  • 1747
  • 1746
  • 1743
  • 1741
  • 1738
  • 1727
  • 1723
  • 1721
  • 1720
  • 1718
  • 1716
  • 1710
  • 1697
  • 1693
  • 1683
  • 1674
  • 1667
  • 1666
  • 1665
  • 1664
  • 1663
  • 1658
  • 1656
  • 1647
  • 1636
  • 1634
  • 1629
  • 1621
  • 1603
  • 1580
  • 1521
  • 1510
  • 1403
  • 1377
  • 1370
  • 1363
  • 1348
  • 1346
  • 1322
  • 1285
  • 1202
  • 1200
  • 1179
  • 1100
  • 1050
  • 541
  • 470
  • 1
Subscribe to E-History

Subscribe

* indicates required

LifeScienceHistory.com

LifeScienceHistory.com Where history is made daily, is a comprehensive companion of life science. Simply put, we dig history and we mine data.

More

  • About
  • Life Science Heroes

Advertising

  • Banner Advertising

Legal

  • Privacy Policy
  • Terms of Use

© 2026 LifeScienceHistory.com by James Web Design

Facebook Instagram Linkedin
  • Home
  • Directory
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • News and History
  • Cartoons
  • Small World
  • Earth is a Rock
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
Search